FORA.tv Speaker - Bertram Lubin
Throughout his career in medicine, Dr. Lubin has directed his energies to fostering biomedical research and has been involved in a number of clinical and basic research projects. His primary research interest has been in sickle cell disease.
He developed a Sickle Cell Screening, Counseling, and Education Program at Children's Hospital Oakland (CHO), and subsequently with a UCSF colleague, started the Northern California Comprehensive Sickle Cell Center, a program that is in its twenty-third year of NIH funding.
Lubin was a member of the NIH Executive Committee that initiated the Cooperative Study of Sickle Cell Disease, a program that supported clinical research in sickle cell disease for over fifteen years. He is an editor of the NIH-published monograph "Current Treatment for Sickle Cell Anemia."
In addition to his interest in clinical hematology, Lubin directed a NIH-funded basic research program to study membrane phospholipid organization in human red blood cells. His group discovered that alterations in membrane phospholipids occurred when cells containing sickle hemoglobin were deoxygenated and that these changes could contribute to clinical events that occur in sickle cell anemia.
Recently, Lubin began the CHO Related Donor Cord Blood Program. The program is offered to families across the United States who currently have a child with a blood disorder such as sickle cell anemia, thalassemia, aplastic anemia, or leukemia, and are expecting another child.
Following the birth of a healthy child, blood remaining in the placenta (cord blood) is harvested. Because cord blood is enriched with bone marrow cells, it is cyropreserved and can later be used for transplantation. A number of lives have been saved following transplantation with cord blood units collected in this program.
07.31.08 | 01:07:29 min
| 3 comments